KOR  ENG

앱클론 로고

Contact

AM105

am105

Bispecific antibody treatment for the simultaneous activation of
immune and anti-cancer cells

AM105 is a bispecific antibody derived from the AffiMab platform that specifically targets
EGFR disease protein and immune cells.

  • AM105
  • AM105 has a dual mode of action for the treatment of cancer. AM105’s first target is
    the CD137 (4-1BB) surface protein of immune cells, while its second target is the
    EGFR disease protein. AM105 minimizes toxicity by nonspecifically activating immune
    cells and can also easily be adapted to treat other cancers by swapping
    out the target disease protein.
  • 앱클론 로고
  • AbClon Inc. #1401 285, Digital-ro, Guro-gu, Seoul, Republic of Korea
    T. +82-2109-1294
    F. +82-2109-1296
    E. abclon@abclon.com
About us
Overview CAR-T GMP History Collaboration Contact Us
Technology
CAR-T platform NEST platform AffiMab platform
Pipeline
AT101 AT501 AC101 AM201 AM105
Antibody Service
Antibody Service
IR/PR
News Stock IR Information
© AbClon. All rights reserved.